Loading…
Tempest Therapeutics, Inc. is projected to rise to $1.81 by 2027, a +1% move from its current price of $1.79. TPST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.71 | $1.79 | $1.88 | -0.02% |
| May 30 | $1.67 | $1.79 | $1.92 | -0.03% |
| May 31 | $1.65 | $1.79 | $1.95 | -0.05% |
| Jun 1 | $1.62 | $1.79 | $1.97 | -0.06% |
| Jun 2 | $1.61 | $1.79 | $1.99 | -0.08% |
| Jun 3 | $1.59 | $1.79 | $2.01 | -0.10% |
| Jun 4 | $1.57 | $1.79 | $2.03 | -0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.57 | $1.79 | $2.03 | -0.11% |
| Week 2 | $1.49 | $1.79 | $2.14 | -0.22% |
| Week 3 | $1.43 | $1.78 | $2.23 | -0.33% |
| Week 4 | $1.38 | $1.78 | $2.30 | -0.45% |
| Week 5 | $1.34 | $1.78 | $2.37 | -0.56% |
| Week 6 | $1.30 | $1.78 | $2.43 | -0.67% |
| Week 7 | $1.27 | $1.78 | $2.49 | -0.78% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company that develops small molecule therapeutics to treat cancer.
Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd.
for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Tempest Therapeutics, Inc. (TPST) is a healthcare stock led by its clinical-stage oncology platform. The current price is $1.86 and the company carries a market capitalization of $27.54M, with a market ranking of 4842.
The price outlook from the provided year-by-year forecast shows a mixed path: 2026’s average is $1.86, moving through years with later potential upside. By 2032 the average target rises to $2.33 with a bullish signal, and by 2040 the average is $2.79 with a bullish signal continuing into 2050, when the average target is $5.46 and the sentiment is bullish. The forecast also notes periods of bear case in the nearer term, including negative ROIs in several years before the later bullish years.
A major floor 24.2% below — a decisive break under it would weaken the trend.
The nearest floor, 5.6% below — buyers have tended to step in here.
The nearest ceiling, 25.1% above — a clean break opens room to run.
A major ceiling 71.5% above — clearing it would confirm fresh momentum.
Key TPST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TPST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.82 | Sell | $1.81 | Sell |
| MA 10 | $1.84 | Sell | $1.84 | Sell |
| MA 20 | $1.92 | Sell | $1.87 | Sell |
| MA 50 | $1.88 | Sell | $2.00 | Sell |
| MA 100 | $2.20 | Sell | $2.68 | Sell |
| MA 200 | $5.15 | Sell | $4.57 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.31 | Neutral |
| Stoch RSI (14) | 10.46 | Buy |
| CCI (20) | -79.25 | Neutral |
| Williams %R (14) | -93.75 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -10.05 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 6.25 | Buy |
| TRIX (15) | -0.11 | Sell |
| Awesome (5,34) | -0.10 | Sell |
| Ultimate (7,14,28) | 42.21 | Neutral |
| Momentum (10) | -0.13 | Sell |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 1.79 | Sell |
| ADX (14) | 11.02 | Neutral |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is Bearish overall.
RSI(14) is 50, which sits near neutral momentum. The near-term moving averages show SMA50 at $1.90 and SMA200 at $5.21, indicating a potential downward bias relative to the longer-term trend.
Support is at $1.69 and resistance at $2.25. The 30-day price range spans from $1.33 to $2.59, highlighting recent volatility within a narrow band around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.52 | $1.79 | $2.31 | 0% | Neutral | |
| $1.33 | $1.81 | $2.67 | +1% | Neutral | |
| $0.999 | $1.43 | $2.23 | -20% | Bearish | |
| $0.9552 | $1.44 | $2.34 | -20% | Bearish | |
| $0.962 | $1.51 | $2.54 | -16% | Bearish | |
| $1.09 | $1.77 | $3.08 | -1% | Neutral | |
| $1.32 | $2.22 | $3.98 | +24% | Bullish | |
| $1.16 | $2.02 | $3.72 | +13% | Neutral | |
| $1.03 | $1.87 | $3.51 | +4% | Neutral | |
| $1.07 | $2.00 | $3.84 | +12% | Neutral | |
| $1.24 | $2.70 | $5.67 | +51% | Bullish | |
| $2.32 | $5.16 | $11.88 | +189% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.52 | $1.79 | $2.14 | +0.00% |
| June 2026 | $1.55 | $1.85 | $2.28 | +3.28% |
| July 2026 | $1.45 | $1.76 | $2.23 | -4.58% |
| August 2026 | $1.42 | $1.74 | $2.24 | -1.26% |
| September 2026 | $1.44 | $1.79 | $2.33 | +2.54% |
| October 2026 | $1.38 | $1.73 | $2.29 | -3.11% |
| November 2026 | $1.31 | $1.66 | $2.21 | -4.28% |
| December 2026 | $1.35 | $1.71 | $2.31 | +3.45% |
Click any year to see its month-by-month TPST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TPST could reach as high as $2.31, with a base case around $1.79 and support toward $1.52 — roughly 0% from $1.79. Price action looks broadly range-bound.
Expect TPST to range from $1.33 to $2.67 through 2027. The $1.81 average target implies a +1% move from current prices. That is up +1% on the projected 2026 average. A consolidation phase looks the most probable path here.
The TPST price prediction for 2028 points to an average of $1.43 (low $0.999, high $2.23) — a potential decline of -20% on today's $1.79. A cyclical pullback looks likely — prices rarely move in a straight line.
In 2029, TPST is projected to trade between $0.9552 and $2.34, averaging $1.44 — a potential decline of -20% from today's $1.79. That is up 0% on the projected 2028 average. Expect choppier, lower action through this leg of the cycle.
Tempest Therapeutics, Inc.'s 2030 outlook centres on $1.51, within a $0.962 to $2.54 range. That is up +5% on the projected 2029 average. That marks a -16% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2031, TPST could reach as high as $3.08, with a base case around $1.77 and support toward $1.09 — roughly -1% from $1.79. A consolidation phase looks the most probable path here.
Expect TPST to range from $1.32 to $3.98 through 2032. The $2.22 average target implies a +24% move from current prices. That is up +26% on the projected 2031 average. Momentum favours further upside here.
The TPST price prediction for 2033 points to an average of $2.02 (low $1.16, high $3.72) — a potential gain of +13% on today's $1.79. A consolidation phase looks the most probable path here.
In 2034, TPST is projected to trade between $1.03 and $3.51, averaging $1.87 — a potential gain of +4% from today's $1.79. That is -8% versus the projected 2033 average. Price action looks broadly range-bound.
Tempest Therapeutics, Inc.'s 2035 outlook centres on $2.00, within a $1.07 to $3.84 range. That is up +7% on the projected 2034 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2040, TPST could reach as high as $5.67, with a base case around $2.70 and support toward $1.24 — roughly +51% from $1.79. Momentum favours further upside here.
Expect TPST to range from $2.32 to $11.88 through 2050. The $5.16 average target implies a +189% move from current prices. That is up +91% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TPST today (≈ 558.659218 TPST) could be worth
$2,885.18
+$1,885.18 (+189%) by 2050 · US Dollar
Based on the average projected TPST price of $5.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TPSTwould be worth at today's price.
$1,000 invested in TPST on May 27, 2025 (≈ 161.812302 TPST) would be worth
$289.64
-$710.36 (-71.0%) today · 0.29× · US Dollar
Based on a TPST entry price of $6.18 vs. today's $1.79.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.86 | $962.37 | -3.8% |
| 1 month ago | $1.72 | $1,040.7 | +4.1% |
| 3 months ago | $2.29 | $781.66 | -21.8% |
| 6 months ago | $3.2 | $559.37 | -44.1% |
| 1 year ago | $6.18 | $289.64 | -71.0% |
| All time (5.0y) ago | $232.05 | $7.71 | -99.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TPST forecast.
Our base-case forecast reaches $3.60 around 2050.
Implied market cap at $3.60: $53.31M
The multi-year forecast shows a mixed but progressively higher path in the outer years. For 2026 the min/avg/max are $1.52/$1.86/$2.44 with a 0% ROI and neutral sentiment. In 2027 the range is $1.36/$1.87/$2.78 with a 0.6% ROI and neutral sentiment, followed by bearish years 2028 ($1.01/$1.46/$2.30, -21.4%), 2029 ($0.9734/$1.48/$2.45, -20.3%), and 2030 ($0.9753/$1.55/$2.66, -16.6%).
The outlook turns neutral in 2031 ($1.11/$1.84/$3.25) before a bullish shift in 2032, where the average rises to $2.33 with a 25.3% ROI and bullish sentiment. 2033–2035 show modest gains/mixed results (avg $2.09, $1.92, $2.09; ROIs 12.2%, 3.3%, 12.2%). The long horizon strengthens in 2040 to an avg of $2.79 with a 49.8% ROI and bullish sentiment, and culminates in 2050 with an avg of $5.46, a max of $12.55, a 193.4% ROI, and bullish sentiment.
Overall, the forecast indicates substantial long-term upside potential with meaningful variability and some near-term downside risk; the strongest upside appears in the 2040–2050 window, while earlier years contain neutral to bearish signals.
Tap a question to reveal the answer.
2030 min $0.9753, avg $1.55, max $2.66, ROI -16.6%, sentiment BEARISH.
The forecast shows a mix of outcomes: 2026 ROI 0%, 2027 ROI 0.6%, and negative ROIs in 2028–2031, followed by positive ROIs in later years (e.g., 25.3% in 2032, 49.8% in 2040, and 193.4% in 2050). These are estimates and not guarantees.
Yes. The 2050 forecast shows an average of $5.46, with a max of $12.55 and a ROI of 193.4%, indicating potential upside by that year.
Current price is $1.86 and market cap is $27.54M.
2032 min $1.35, avg $2.33, max $4.24, ROI 25.3%, sentiment BULLISH.
Tempest Therapeutics, Inc. Community Discussion
0Share your Tempest Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.